DOI QR코드

DOI QR Code

Determination of calcium content and dissolution characteristics of oyster shell by ICP-AES

유도결합플라즈마 원자방출분광법을 이용한 모려 칼슘의 함량 및 용출 특성 분석

  • Received : 2010.07.06
  • Accepted : 2010.07.29
  • Published : 2010.08.25

Abstract

An ICP-AES method for determination of calcium content and dissolution characteristics of oyster shell (Ostrea gigas) has been developed and validated. Total calcium content in oyster shell was determined using ICPAES. The dissolution characteristics, which would reflect the composition of $CaCO_3$ polymorphs and calcium salts in oyster shell, were also evaluated by dissolution test. The total calcium contents ranged from 31.8 to 39.9% and the dissolution ratios varied from 62.7 to 83.6% (n=15). The determination of calcium content and dissolution characteristics by ICP-AES would provide useful information for the quality control of oyster shell.

Keywords

oyster shell;calcium;dissolution;polymorphism;ICP-AES

References

  1. 생약학연구회, "현대생약학", 10판, p. 190, 학창사, 서울, 2004.
  2. 한방약리학교재편찬위원회, "한방약리학", p. 46, 신일상사, 서울, 2005.
  3. 무기약품제조학분과회, "무기의약품화학", 2판, p. 246-250, 동명사, 서울, 2007.
  4. 정의영, 김진희, 류동기, 박갑만, 박관하, 박성우, 소재귀, 신윤경, 이정식, 이정열, 이창훈, 최진우, 허영백, "연체동물 이매패류의 생리생태", p. 23-25, 바이오사이언스, 서울, 2008.
  5. C. S. Choi and Y. W. Kim, Biomaterials, 21(3), 213-222(2000). https://doi.org/10.1016/S0142-9612(99)00120-9
  6. J. M. Lee, A. J. Park, S. M. Cho and K. D. Park, Korean J. Malacol., 24(2), 109-119(2008).
  7. 홍남두, 김남재, "한약의 품질관리", p. 88-92, 신일상사, 서울, 2004.
  8. 식품의약품안전청 고시 제2007-89호, 대한약전 제 9 개정(2007.12.28.).
  9. 식품의약품안전청 고시 제2007-90호, 대한약전외한약(생약)규격집(2007.12.28.).
  10. S. W. Lee and C. S. Choi, Micron, 38(1), 58-64(2007). https://doi.org/10.1016/j.micron.2006.03.018
  11. European Pharmacopoeia Commission, European Pharmacopoeia 6.0 <2.2.57> Inductive Coupled Plasma-Atomic Emission Spectrometry, 2008.
  12. 식품의약품안전청 고시 제2010-37호, 의약품등의 품목허가 신고 심사 규정(2010.5.31.)
  13. 이범진, 한건, "제형의 원리와 기술", 2판, p. 130-138, 신일상사, 서울, 2005.
  14. Y. T. Sohn and H. K. Kim, J. Kor. Pharm. Sci., 28(2), 81-85(1998).
  15. H. G. Brittain, "Polymorphism in pharmaceutical solids", Informa healthcare, p. 321-325, New York, 2007.
  16. H. B. Stenzel, Sci., 142(3589), 232-233(1963). https://doi.org/10.1126/science.142.3589.232
  17. J. MacDonald, A. Freer and M. Cusack, Cryst. Growth & Des., 10(3), 1243-1246(2010). https://doi.org/10.1021/cg901263p
  18. S. W. Lee, Y. M. Kim, R. H. Kim and C. S. Choi, Micron, 39(4), 380-386(2008). https://doi.org/10.1016/j.micron.2007.03.006
  19. A. Gutjahr, H. Dabringhaus and R. Lacmann, J. Crystal growth, 158(3), 296-309(1996). https://doi.org/10.1016/0022-0248(95)00446-7
  20. J. K. Bass and G. M. Chan, Nutrition, 22(10), 1057-1066(2006). https://doi.org/10.1016/j.nut.2006.05.014
  21. L. Fishbein, Regul. Toxicol. Pharmacol., 39(2), 67-80(2004). https://doi.org/10.1016/j.yrtph.2003.11.002
  22. A. Gutjahr, H. Dabringhaus and R. Lacmann, J. Crystal growth, 158(3), 310-315(1996). https://doi.org/10.1016/0022-0248(95)00447-5
  23. S. Azarmi, W. Roa and R. Lobenberg, Int. J. Pharm., 328(1), 12-21(2007). https://doi.org/10.1016/j.ijpharm.2006.10.001